Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Focus Group Testing For Health Claim Consumer Perception Advised By CSPI

This article was originally published in The Tan Sheet

Executive Summary

FDA should use focus groups to determine whether consumers understand or are misled by health claims on foods and dietary supplements, according to comments submitted to FDA June 4 by the Center for Science in the Public Interest

You may also be interested in...



Health claims debate

Firms value authorized health claims "much more" than qualified claims "and will always prefer an authorized claim to an unauthorized one and only thereafter an unauthorized one to none at all," supplement marketers say in July 1 comments to FDA. Filed on behalf of Life Extension Foundation and Julian Whitaker, MD, by Washington, D.C-based Emord & Associates, comments respond to CSPI assertions that qualified claims eliminate incentive for authorized claims. On the contrary, the "two-tiered claim approach has the effect of encouraging research because rather than an all-or-nothing [significant scientific agreement] option, the fact that a qualified claim exists affords enough security to justify risking capital," comments state. Firms also maintain CSPI, in criticizing health claims, ignores Pearson rulings forcing FDA to favor disclaimers over speech suppression. CSPI filed comments in June (1"The Tan Sheet" June 9, 2003, p. 16)...

Health claims debate

Firms value authorized health claims "much more" than qualified claims "and will always prefer an authorized claim to an unauthorized one and only thereafter an unauthorized one to none at all," supplement marketers say in July 1 comments to FDA. Filed on behalf of Life Extension Foundation and Julian Whitaker, MD, by Washington, D.C-based Emord & Associates, comments respond to CSPI assertions that qualified claims eliminate incentive for authorized claims. On the contrary, the "two-tiered claim approach has the effect of encouraging research because rather than an all-or-nothing [significant scientific agreement] option, the fact that a qualified claim exists affords enough security to justify risking capital," comments state. Firms also maintain CSPI, in criticizing health claims, ignores Pearson rulings forcing FDA to favor disclaimers over speech suppression. CSPI filed comments in June (1"The Tan Sheet" June 9, 2003, p. 16)...

Health claims debate

Firms value authorized health claims "much more" than qualified claims "and will always prefer an authorized claim to an unauthorized one and only thereafter an unauthorized one to none at all," supplement marketers say in July 1 comments to FDA. Filed on behalf of Life Extension Foundation and Julian Whitaker, MD, by Washington, D.C-based Emord & Associates, comments respond to CSPI assertions that qualified claims eliminate incentive for authorized claims. On the contrary, the "two-tiered claim approach has the effect of encouraging research because rather than an all-or-nothing [significant scientific agreement] option, the fact that a qualified claim exists affords enough security to justify risking capital," comments state. Firms also maintain CSPI, in criticizing health claims, ignores Pearson rulings forcing FDA to favor disclaimers over speech suppression. CSPI filed comments in June (1"The Tan Sheet" June 9, 2003, p. 16)...

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS095554

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel